Merck returns to Alzheimer’s disease with $1.1B Cerevance pact
Merck returns to Alzheimer’s disease with $1.1B Cerevance pact Published: Aug 09, 2022 By Alex Keown BioSpace With an investment valued at up to
Tag : Alzheimer's Disease
2 min read
Eli Lilly cuts annual profit view as lower insulin prices hit Q2 sales
Eli Lilly cuts annual profit view as lower insulin prices hit Q2 sales Aug 4 (Reuters) – Eli Lilly and Co. (LLY.N) on Thursday cut its full-year
2 min read
New research uses magnetic nanoparticles to manipulate genomic loci
Written by Miyako Rogers, Science Writer Research published in Science describes an innovative new technique to manipulate specific genomic loci
2 min read
Roche grasps at Alzheimer’s and goes big on blood cancers with Poseida
Roche grasps at Alzheimer’s and goes big on blood cancers with Poseida Published: Aug 03, 2022 By Mark Terry BioSpace Roche signed a $6
Genomic analysis reveals recombination hot spots and gives insights into Alzheimer’s and Parkinson’s Disease
Written by Miyako Rogers, Science Writer New research published in Cell involving large-scale genomic analysis of human tissue samples has shown that
Balancing Sandwich Generation Caregiving Relationships with Grace
Caregiving can creep into your life or crash down with a bang, but either way, if we aren’t thinking ahead, we can find that our other
2 min read
EverythingALS and NeuroSense take aim at Lou Gehrig’s disease
NeuroSense Therapeutics (NASDAQ:NRSN) and ALS-fighter, EverythingALS, are collaborating to identify treatments and a cure for ALS. EverythingALS was
Why Are There No Effective Alzheimer’s Drugs?
There are now over 6 million people in the U.S. with Alzheimer’s disease. The World Alzheimer Report from 2018 estimates that 50 million people are
4 min read
Cassava Sciences faces U.S. criminal probe tied to Alzheimer’s drug, sources say
Cassava Sciences faces U.S. criminal probe tied to Alzheimer’s drug, sources say By Marisa Taylor and Mike Spector WASHINGTON, July 27 (Reuters)
1 min read
U.S. FDA grants priority review to Biogen’s ALS drug
U.S. FDA grants priority review to Biogen’s ALS drug July 26 (Reuters) – The U.S. Food and Drug Administration has agreed to review Biogen
2 min read
RNA sequencing untangles the most significant genetic risk factor for Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million
5 min read
‘For me, the truth is important because we have been fed so many books with lies’—An interview with Terry-Ann Adams on their new collection of short stories, White Chalk
The JRB Editor Jennifer Malec chatted to Terry-Ann Adams about writing, representation, and their new collection of short stories, White
2 min read
AbbVie half breaks up with Alector on Alzheimer’s
AbbVie half breaks up with Alector on Alzheimer’s Published: Jul 08, 2022 By Vanessa Doctor, RN BioSpace AbbVie has ended its collaboration deal
Do ADHD Drugs Help People with Alzheimer Disease?
Most of the medications currently used to treat Alzheimer disease work by increasing acetylcholine levels in the brain. This neurotransmitter is
2 min read
Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan
The FDA has started an accelerated review of Eisai and Biogen’s a new amyloid-targeting antibody lecanemab for Alzheimer’s disease, with a 6